EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Vedolizumab: Beyond Inflammatory Bowel Disease

Yafang Li, Minli Hu, Yuan Chen, Xiao-Yun Yang, Qunying Wang, Jin Ding, Yibing Hu

Medical Principles and Practice · 2025

DOI: 10.1159/000547015 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Principles and Practice, 2025. Verfasst von Yafang Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Gastrointestinal Agents, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Health of Zhejiang Province, Science and Technology Plan Project of Jinhua Municipal Central Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vedolizumab (VDZ) is a key therapeutic option for inflammatory bowel disease (IBD) patients, not responding to conventional treatments. An α4β7 integrin antagonist, VDZ, primarily prevents T-cell migration to the gut by inhibiting the binding of integrins to mucosal vascular address in cellular adhesion molecule. Its gut-selective mechanism of action and safety profile makes it a valuable intervention for treating non-IBD-related diseases, which are difficult to treat and lack standardized guidelines. There is plenty of evidence to suggest that VDZ has therapeutic potential beyond its primary indication in IBD, with clinical applications now extending to immune checkpoint inhibitor-associated colitis, chronic pouchitis, gastrointestinal graft-versus-host disease, and acquired immunodeficiency syndrome. This review aimed to analyze the therapeutic value of VDZ for non-IBD-related diseases and provide a reference for treating these patients. It has been observed that long-term follow-up data are lacking, and additional well-designed large-scale studies are still needed to further validate the efficacy and safety of VDZ.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGastrointestinal AgentsInflammatory Bowel DiseasesHumansGraft vs Host DiseasePouchitisIntegrins

Stichwörter der Autor:innen

Acquired immune deficiency syndromeChronic pouchitisGastrointestinal graft-versus-host diseaseImmune checkpoint inhibitor-associated colitisVedolizumab

Substanzen

vedolizumabAntibodies, Monoclonal, HumanizedGastrointestinal AgentsIntegrins

Autor:innen und Institutionen

  • Department of Gastroenterology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.

Förderung

  • Department of Health of Zhejiang Province
  • Science and Technology Plan Project of Jinhua Municipal Central Hospital

Zitieren

APA

Li, Y., Hu, M., Chen, Y., Yang, X. Y., Wang, Q., Ding, J., & Hu, Y. (2025). Vedolizumab: Beyond Inflammatory Bowel Disease. Medical Principles and Practice. https://doi.org/10.1159/000547015

Vancouver

Li Y, Hu M, Chen Y, Yang XY, Wang Q, Ding J, et al. Vedolizumab: Beyond Inflammatory Bowel Disease. Medical Principles and Practice. 2025. doi:10.1159/000547015

BibTeX
@article{Li2025,
  author = {Li, Yafang and Hu, Minli and Chen, Yuan and Yang, Xiao-Yun and Wang, Qunying and Ding, Jin and Hu, Yibing},
  title = {Vedolizumab: Beyond Inflammatory Bowel Disease},
  journal = {Medical Principles and Practice},
  year = {2025},
  doi = {10.1159/000547015}
}
Kostenlos starten →